DARTRIX ‘DARPin Targeted RX (therapy)’ is a multidisciplinary collaborative project that will develop high-affinity protein scaffolds to create a new generation of targeted therapeutics for the treatment of
The DARTRIX concept provides a completely novel approach to cancer therapy. It will therefore
be necessary to test and optimise many diverse parameters in order to deliver our objective – a DARPin-targeted medical device for safe and efficient treatment of glioblastoma. The ambitious aim of the DARTRIX consortium is to prepare the device for commercial development within 60
months taking a multidisciplinary approach, combining academic, clinical and industrial expertise. Using this expertise, we will tackle the clinical and laboratory development of DARTRIX simultaneously. Thus, available DARPins will be used to create the first DARTRIX particle, to pioneer the therapy and obtain critical information on safety, dosing and immunogenicity in man. A new generation of engineered and modified DARPins will be developed to synergistically
create an improved range of particles specifically tailored to address the heterogeneity of glioblastoma
and provide more efficient and personalised treatment.
Figure, DARTRIX particle. Super-paramagnetic iron oxide nanoparticles (SPION) have potential for cancer therapy. SPION are biocompatible and used safely in clinical practice as systemically administered magnetic resonance imaging (MRI) contrast agents. SPION can also be induced to generate heat by application of an alternating magnetic field. Functionalising SPION with tumour-selective DARPins offers the exciting possibility of targeting MRI-tracked SPIONs to tumours, followed by application of a magnetic field resulting in effective localised hyperthermic therapy.